Premium
CA 494—a new tumor marker for the diagnosis of pancreatic cancer
Author(s) -
Friess Helmut,
Büchler Markus,
Auerbach Bernhard,
Weber Alexander,
Malfertheiner Peter,
Hammer Kai,
Madry Norbert,
Greiner Sabine,
Bosslet Klaus,
Beger Hans G.
Publication year - 1993
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910530509
Subject(s) - pancreatic cancer , medicine , ca19 9 , pancreatitis , pancreatic disease , pancreas , gastroenterology , monoclonal antibody , cancer , gastrointestinal cancer , population , tumor marker , pathology , antibody , immunology , colorectal cancer , environmental health
In 59 patients with ductal pancreatic cancer the monoclonal antibody (MAb) BW 494, which detects the CA 494 glycoprotein antigen, was analyzed in comparison with the reference tumor markers CA 19‐9 and CEA. Eighty‐one patients with non‐pancreatic malignancies of the gastraintestinal (GI) tract, 95 with chronic pancreatitis, 124 with benign non‐pancreatic GI diseases, 30 with diabetes mellitus (type I or type II) and I14 healthy blood donors served as controls. The sensitivity of pancreatic cancer was 90%, 44% and 90% for CA 19‐9, CEA and CA 494, respectively. In chronic pancreatitis, as the most important control population for pancreatic cancer, the specificity was 85%, 72% and 94% for CA 19‐9, CEA and CA 494, respectively.